title: Bovine surfactant therapy for patients with acute respiratory distress syndrome.
abstract: Lung surfactant is deficient in patients with acute respiratory distress syndrome (ARDS). We performed a randomized, prospective, controlled, open-label clinical study of administration of a bovine surfactant to patients with ARDS to obtain preliminary information about its safety and efficacy. Patients received either surfactant by endotracheal instillation in addition to standard therapy or standard therapy only. Three different groups of patients receiving surfactant were studied: patients receiving up to eight doses of 50 mg phospholipids/kg, those receiving up to eight doses of 100 mg phospholipids/kg, and those receiving up to four doses of 100 mg phospholipids/kg. Outcome measures included ventilatory support parameters, arterial blood gases, organ system failures, bronchoalveolar lavage (BAL) analyses, immunologic analyses, survival, and adverse events during the 28-d study period. Fifty-nine study patients were evaluable; 43 in the surfactant group and 16 in the control group. The FI(O2) at 120 h after treatment began was significantly decreased only for patients who received up to four doses of 100 mg phospholipids/kg surfactant as compared with control patients (p = 0.011). Mortality in the same group of patients was 18.8%, as compared with 43.8% in the control group (p = 0.075). The surfactant instillation was generally well tolerated, and no safety concerns were identified. This pilot study presents preliminary evidence that surfactant might have therapeutic benefit for patients with ARDS, and provides rationale for further clinical study of this agent.
authors.affiliation: Department of Internal Medicine, Ohio State University Hospital, Columbus, USA.
authors.forename: T J
authors.initials: TJ
authors.lastname: Gregory
authors.forename: K P
authors.initials: KP
authors.lastname: Steinberg
authors.forename: R
authors.initials: R
authors.lastname: Spragg
authors.forename: J E
authors.initials: JE
authors.lastname: Gadek
authors.forename: T M
authors.initials: TM
authors.lastname: Hyers
authors.forename: W J
authors.initials: WJ
authors.lastname: Longmore
authors.forename: M A
authors.initials: MA
authors.lastname: Moxley
authors.forename: G Z
authors.initials: GZ
authors.lastname: Cai
authors.forename: R D
authors.initials: RD
authors.lastname: Hite
authors.forename: R M
authors.initials: RM
authors.lastname: Smith
authors.forename: L D
authors.initials: LD
authors.lastname: Hudson
authors.forename: C
authors.initials: C
authors.lastname: Crim
authors.forename: P
authors.initials: P
authors.lastname: Newton
authors.forename: B R
authors.initials: BR
authors.lastname: Mitchell
authors.forename: A J
authors.initials: AJ
authors.lastname: Gold
mesh_terms: D000328:Adult; D000818:Animals; D001688:Biological Products; D002417:Cattle; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000401:mortality / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D011663:Pulmonary Surfactants; C072197:beractant